Literature DB >> 16563863

Pulmonary and vascular pharmacology of sphingosine 1-phosphate.

Volker Brinkmann1, Thomas Baumruker.   

Abstract

Dysregulation of vasomotor tone, endothelial barrier function and immune cell trafficking are central to the pathology of many lung diseases, including acute lung injury, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma. There is increasing evidence that the serum sphingolipid sphingosine 1-phosphate and its G-protein-coupled receptors are pivotal not only in the regulation of lymphocyte migration, but also in the maintenance of vascular homeostasis and the preservation of permeability barriers that separate discrete compartments in the lung.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563863     DOI: 10.1016/j.coph.2005.12.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  18 in total

1.  Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.

Authors:  Robert Schmouder; Sam Hariry; Olivier J David
Journal:  Eur J Clin Pharmacol       Date:  2011-11-10       Impact factor: 2.953

Review 2.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  Functional variants of the sphingosine-1-phosphate receptor 1 gene associate with asthma susceptibility.

Authors:  Xiaoguang Sun; Shwu-Fan Ma; Michael S Wade; Carlos Flores; Maria Pino-Yanes; Jaideep Moitra; Carole Ober; Rick Kittles; Aliya N Husain; Jean G Ford; Joe G N Garcia
Journal:  J Allergy Clin Immunol       Date:  2010-07-10       Impact factor: 10.793

4.  Fingolimod and cardiac risk: latest findings and clinical implications.

Authors:  Wendy S Vargas; Jai S Perumal
Journal:  Ther Adv Drug Saf       Date:  2013-06

Review 5.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

6.  A common cortactin gene variation confers differential susceptibility to severe asthma.

Authors:  Shwu-Fan Ma; Carlos Flores; Michael S Wade; Steven M Dudek; Dan L Nicolae; Carole Ober; Joe G N Garcia
Journal:  Genet Epidemiol       Date:  2008-12       Impact factor: 2.135

7.  A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome.

Authors:  Joyce A Bonitz; Julie Y Son; Benjamin Chandler; Jacquelyn N Tomaio; Yong Qin; Lauriston M Prescott; Eleonora Feketeova; Edwin A Deitch
Journal:  Shock       Date:  2014-11       Impact factor: 3.454

Review 8.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

Review 9.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

10.  Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers.

Authors:  Magdalena Ocwieja; Karin Meiser; Olivier J David; Jessica Valencia; Frank Wagner; Stephan J Schreiber; Uwe Pleyer; Sabine Ziemer; Robert Schmouder
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.